Antibodies to beta(2)-glycoprotein (beta(2)-GPI) have been associated with recurrent thrombotic events in patients with systemic lupus erythematosus. The present study investigated the prevalence of antibodies to beta(2)-GPI in an unselected group of patients with ischemic stroke. One hundred and twenty-one sera from patients with ischemic stroke and 174 control sera from patients with nonischemic neurological disorders (n = 43) and healthy subjects (n = 131) were tested for antibodies to beta(2)-GPI by a solid-phase ELISA. Twenty-nine stroke patients (24%) had antibodies to beta(2)-GPI. Of the 43 patients in the neurological control group, 2 were positive. For comparison between the groups, Fisher's exact test was used for categorical variables and ANOVA for antibody titers. Antibody levels and frequencies of positivity were significantly different between the study groups. None of the sera from the healthy control group had abnormal antibody levels. When risk factors and associated diseases were taken into account, a marginal association was found between the presence of antibodies to beta(2)-GPI and hypertension (p = 0.036). This study demonstrates a significant prevalence of antibodies to beta(2)-GPI in an unselected stroke population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000016073 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inhibiting Tyrosine Kinase 2 Ameliorates Antiphospholipid Syndrome Nephropathy.
Mediators Inflamm
January 2025
Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
Article Synopsis
- Antiphospholipid antibody syndrome (APS) is an autoimmune disease that causes blood vessel problems and can lead to serious kidney damage known as nephropathy.
- Researchers tested a Tyk2 inhibitor, BMS-986202, on mice with APS nephropathy to assess its effects on the disease.
- The study found that Tyk2 inhibition not only improved kidney function and reversed harmful changes in the kidneys, but also reduced the type I interferon (IFN) signature associated with the disease, indicating a potential new treatment approach for APS nephropathy.
Interpreting high levels of unfolded Von Willebrand Factor in patients with the antiphospholipid syndrome.
Front Immunol
December 2024
Coagulation Laboratory, Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium.
Introduction: Unfolded Von Willebrand Factor (VWF) is increased in thrombotic pathologies such as myocardial infarction. Unfolded VWF mediates the binding of platelets without the need for collagen. β-glycoprotein I (β-GPI) is a natural inhibitor of the platelet-VWF interaction.
View Article and Find Full Text PDFAntibody profiles in the mosaic of 'seronegative' APS syndrome.
Clin Exp Immunol
November 2024
Dipartimento di Medicina Sperimentale, Sapienza University, Rome, Italy.
Clinical manifestations, as distinct from thrombotic and obstetric morbidity, were recently included in the update of classification criteria of the antiphospholipid syndrome (APS). However, the existence of several patients with clinical manifestations suggestive of APS, but negative for criteria antiphospholipid antibodies (aPLs) [anti-cardiolipin antibodies (aCL), anti-β2-glycoprotein I antibodies (aβ2-GPI), and lupus anticoagulant] may suggest an update of diagnostic criteria. In this study, we analysed the prevalence of six non-criteria aPLs in a large monocentric cohort of patients with seronegative APS (SN-APS), to investigate their possible diagnostic role.
View Article and Find Full Text PDFThe association between antiphospholipid syndrome and atrial fibrillation: a single center retrospective case-control study.
PeerJ
July 2024
Department of Cardiology, Peking University People's Hospital, Beijing, China.
Article Synopsis
- Antiphospholipid syndrome (APS) is an autoimmune disorder linked to blood clots, pregnancy issues, and low platelet counts, and this study explored its connection to atrial fibrillation (AF) at Peking University People's Hospital.
- A retrospective study compared hospitalized AF patients diagnosed by cardiologists with a control group of patients without cardiac diseases.
- Results showed that APS and the presence of specific antibodies (anticardiolipin and anti-beta-2-glycoprotein) are independent risk factors for AF, warranting further research to better understand this relationship.
Management of Cardiovascular Complications in Antiphospholipid Syndrome: A Narrative Review with a Focus on Older Adults.
J Clin Med
May 2024
Department of Geriatrics, Orthopedics, and Rheumatology, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168 Rome, Italy.
Antiphospholipid syndrome (APS), also known as Hughes syndrome, is an acquired autoimmune and procoagulant condition that predisposes individuals to recurrent thrombotic events and obstetric complications. Central is the role of three types of antiphospholipid antibodies that target phospholipid-binding proteins: lupus anticoagulant (LAC), anti-β2-glycoprotein I (β2-GPI-Ab), and anti-cardiolipin (aCL). Together with clinical data, these antibodies are the diagnostic standard.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!